Researchers at Johns Hopkins University have developed an integrated genomic approach that potentially could help physicians predict which patients with non-small cell lung cancer will respond to therapy with immune checkpoint inhibitors.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
